Cannabinoids for the Treatment of Dermatologic Conditions
In recent years, cannabinoid (CB) products have gained popularity among the public. The anti-inflammatory properties of CBs have piqued the interest of researchers and clinicians because they represent promising avenues for the treatment of autoimmune and inflammatory skin disorders that may be refr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | JID Innovations |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667026722000017 |
| _version_ | 1819158943640846336 |
|---|---|
| author | Torunn E. Sivesind Jalal Maghfour Hope Rietcheck Kevin Kamel Ali S. Malik Robert P. Dellavalle |
| author_facet | Torunn E. Sivesind Jalal Maghfour Hope Rietcheck Kevin Kamel Ali S. Malik Robert P. Dellavalle |
| author_sort | Torunn E. Sivesind |
| collection | DOAJ |
| description | In recent years, cannabinoid (CB) products have gained popularity among the public. The anti-inflammatory properties of CBs have piqued the interest of researchers and clinicians because they represent promising avenues for the treatment of autoimmune and inflammatory skin disorders that may be refractory to conventional therapy. The objective of this study was to review the existing literature regarding CBs for dermatologic conditions. A primary literature search was conducted in October 2020, using the PubMed and Embase databases, for all articles published from 1965 to October 2020. Review articles, studies using animal models, and nondermatologic and pharmacologic studies were excluded. From 248 nonduplicated studies, 26 articles were included. There were 13 articles on systemic CBs and 14 reports on topical CBs. Selective CB receptor type 2 agonists were found to be effective in treating diffuse cutaneous systemic sclerosis and dermatomyositis. Dronabinol showed efficacy for trichotillomania. Sublingual cannabidiol and Δ-9-tetrahydrocannabinol were successful in treating the pain associated with epidermolysis bullosa. Available evidence suggests that CBs may be effective for the treatment of various inflammatory skin disorders. Although promising, additional research is necessary to evaluate efficacy and to determine dosing, safety, and long-term treatment guidelines. |
| first_indexed | 2024-12-22T16:32:41Z |
| format | Article |
| id | doaj.art-07ce9ce2e4a44f07b96fb6bea19c6468 |
| institution | Directory Open Access Journal |
| issn | 2667-0267 |
| language | English |
| last_indexed | 2024-12-22T16:32:41Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JID Innovations |
| spelling | doaj.art-07ce9ce2e4a44f07b96fb6bea19c64682022-12-21T18:20:01ZengElsevierJID Innovations2667-02672022-03-0122100095Cannabinoids for the Treatment of Dermatologic ConditionsTorunn E. Sivesind0Jalal Maghfour1Hope Rietcheck2Kevin Kamel3Ali S. Malik4Robert P. Dellavalle5Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USADepartment of Dermatology and Skin Care, Henry Ford Health System, Detroit, Michigan, USADepartment of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USASchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USADepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USADepartment of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; Rocky Mountain Regional VA Medical Center, U.S. Department of Veterans Affairs, Aurora, Colorado, USA; Correspondence: Robert P. Dellavalle, Dermatology Service, Rocky Mountain Regional VA Medical Center, U.S. Department of Veterans Affairs, Colorado School of Public Health, Room E1-342, 1700 North Wheeling Street, Aurora, Colorado 80045, USA.In recent years, cannabinoid (CB) products have gained popularity among the public. The anti-inflammatory properties of CBs have piqued the interest of researchers and clinicians because they represent promising avenues for the treatment of autoimmune and inflammatory skin disorders that may be refractory to conventional therapy. The objective of this study was to review the existing literature regarding CBs for dermatologic conditions. A primary literature search was conducted in October 2020, using the PubMed and Embase databases, for all articles published from 1965 to October 2020. Review articles, studies using animal models, and nondermatologic and pharmacologic studies were excluded. From 248 nonduplicated studies, 26 articles were included. There were 13 articles on systemic CBs and 14 reports on topical CBs. Selective CB receptor type 2 agonists were found to be effective in treating diffuse cutaneous systemic sclerosis and dermatomyositis. Dronabinol showed efficacy for trichotillomania. Sublingual cannabidiol and Δ-9-tetrahydrocannabinol were successful in treating the pain associated with epidermolysis bullosa. Available evidence suggests that CBs may be effective for the treatment of various inflammatory skin disorders. Although promising, additional research is necessary to evaluate efficacy and to determine dosing, safety, and long-term treatment guidelines.http://www.sciencedirect.com/science/article/pii/S2667026722000017 |
| spellingShingle | Torunn E. Sivesind Jalal Maghfour Hope Rietcheck Kevin Kamel Ali S. Malik Robert P. Dellavalle Cannabinoids for the Treatment of Dermatologic Conditions JID Innovations |
| title | Cannabinoids for the Treatment of Dermatologic Conditions |
| title_full | Cannabinoids for the Treatment of Dermatologic Conditions |
| title_fullStr | Cannabinoids for the Treatment of Dermatologic Conditions |
| title_full_unstemmed | Cannabinoids for the Treatment of Dermatologic Conditions |
| title_short | Cannabinoids for the Treatment of Dermatologic Conditions |
| title_sort | cannabinoids for the treatment of dermatologic conditions |
| url | http://www.sciencedirect.com/science/article/pii/S2667026722000017 |
| work_keys_str_mv | AT torunnesivesind cannabinoidsforthetreatmentofdermatologicconditions AT jalalmaghfour cannabinoidsforthetreatmentofdermatologicconditions AT hoperietcheck cannabinoidsforthetreatmentofdermatologicconditions AT kevinkamel cannabinoidsforthetreatmentofdermatologicconditions AT alismalik cannabinoidsforthetreatmentofdermatologicconditions AT robertpdellavalle cannabinoidsforthetreatmentofdermatologicconditions |